133 filings
Page 2 of 7
8-K
3oyqg46wikrz4c4y2l
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
8-K
izp51xla
29 Mar 22
Tempest Reports Year End 2021 Financial Results and Provides Corporate Highlights
4:41pm
8-K
qy5psslnwf3ej1itsjh
23 Dec 21
Departure of Directors or Certain Officers
4:08pm
8-K
gt8 3u3581dz
10 Nov 21
Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights
3:54pm
8-K/A
sehkcs3
30 Sep 21
Departure of Directors or Certain Officers
10:47am
8-K
god7uqq
24 Sep 21
Amendments to Articles of Incorporation or Bylaws
11:03am
8-K
cev79f83b5kzx 9c
12 Aug 21
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights
4:23pm
8-K
nr1sjhs176w6oklq8s0
23 Jul 21
Other Events
5:20pm
8-K
m8ypp6ky zod
16 Jul 21
Other Events
4:31pm
8-K
n7qob18oe1 t3ltqtg
12 Jul 21
Departure of Directors or Certain Officers
8:51am
8-K
tqtil
7 Jul 21
Departure of Directors or Certain Officers
5:18pm
8-K/A
zas33zch
1 Jul 21
Changes in Registrant's Certifying Accountant
4:44pm
8-K
cwu hqst4ls4zi
28 Jun 21
Tempest Closes Merger with Millendo and Completes PIPE Financing
8:51am
8-K
cj3iifr15yc
22 Jun 21
Tempest and Millendo Announce Stockholder Approval of Merger
9:10pm
8-K
31yewvquuqgpahvh
11 Jun 21
Other Events
5:21pm
8-K
7l6fkoz
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
8-K
b0wqc8whjo9j7
28 Jan 21
Cost Associated with Exit or Disposal Activities
8:01am
8-K
c0pe 8dvc1ymmixqh
5 Jan 21
Millendo Therapeutics Provides Pipeline and Business Update
9:08am
8-K
1ojls
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
74oalvg0s8bwl k8l80m
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am